Cargando…

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors

BACKGROUND: We evaluated whether tumor infiltrating lymphocytes (TIL) could be expanded from surgically resected tumors from pancreatic cancer patients. METHODS: Tumors were resected from pancreatic cancer patients. Tumors were minced into fragments and cultured in media containing high dose interle...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, MacLean, Liu, Hao, Malafa, Mokenge, Centeno, Barbara, Hodul, Pamela J., Pimiento, José, Pilon-Thomas, Shari, Sarnaik, Amod A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067894/
https://www.ncbi.nlm.nih.gov/pubmed/27777771
http://dx.doi.org/10.1186/s40425-016-0164-7
_version_ 1782460726408904704
author Hall, MacLean
Liu, Hao
Malafa, Mokenge
Centeno, Barbara
Hodul, Pamela J.
Pimiento, José
Pilon-Thomas, Shari
Sarnaik, Amod A.
author_facet Hall, MacLean
Liu, Hao
Malafa, Mokenge
Centeno, Barbara
Hodul, Pamela J.
Pimiento, José
Pilon-Thomas, Shari
Sarnaik, Amod A.
author_sort Hall, MacLean
collection PubMed
description BACKGROUND: We evaluated whether tumor infiltrating lymphocytes (TIL) could be expanded from surgically resected tumors from pancreatic cancer patients. METHODS: Tumors were resected from pancreatic cancer patients. Tumors were minced into fragments and cultured in media containing high dose interleukin-2 (IL-2) for up to 6 weeks. T cell phenotype, activation markers, and reactivity were measured. RESULTS: TIL expansion was measured in 19 patient samples. The majority of these TIL were CD4(+) T cells and were highly activated. Purified CD8(+) T cells produced IFN-γ in response to HLA-matched pancreatic tumor targets. PD-1 blockade and 4-1BB stimulation were demonstrated as effective strategies to improve effective TIL yield, including the production of tumor-reactive pancreatic TIL. CONCLUSIONS: TIL expanded from pancreatic tumors are functional and able to respond to pancreatic tumor associated antigens. PD-1 blockade, 41BB stimulation, and CD8(+) T cell enrichment are effective strategies to improve TIL yield and tumor reactivity. These results support the development of adoptive cell therapy strategies using TIL for the treatment of pancreatic cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40425-016-0164-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5067894
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50678942016-10-24 Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors Hall, MacLean Liu, Hao Malafa, Mokenge Centeno, Barbara Hodul, Pamela J. Pimiento, José Pilon-Thomas, Shari Sarnaik, Amod A. J Immunother Cancer Research Article BACKGROUND: We evaluated whether tumor infiltrating lymphocytes (TIL) could be expanded from surgically resected tumors from pancreatic cancer patients. METHODS: Tumors were resected from pancreatic cancer patients. Tumors were minced into fragments and cultured in media containing high dose interleukin-2 (IL-2) for up to 6 weeks. T cell phenotype, activation markers, and reactivity were measured. RESULTS: TIL expansion was measured in 19 patient samples. The majority of these TIL were CD4(+) T cells and were highly activated. Purified CD8(+) T cells produced IFN-γ in response to HLA-matched pancreatic tumor targets. PD-1 blockade and 4-1BB stimulation were demonstrated as effective strategies to improve effective TIL yield, including the production of tumor-reactive pancreatic TIL. CONCLUSIONS: TIL expanded from pancreatic tumors are functional and able to respond to pancreatic tumor associated antigens. PD-1 blockade, 41BB stimulation, and CD8(+) T cell enrichment are effective strategies to improve TIL yield and tumor reactivity. These results support the development of adoptive cell therapy strategies using TIL for the treatment of pancreatic cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40425-016-0164-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-18 /pmc/articles/PMC5067894/ /pubmed/27777771 http://dx.doi.org/10.1186/s40425-016-0164-7 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hall, MacLean
Liu, Hao
Malafa, Mokenge
Centeno, Barbara
Hodul, Pamela J.
Pimiento, José
Pilon-Thomas, Shari
Sarnaik, Amod A.
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
title Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
title_full Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
title_fullStr Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
title_full_unstemmed Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
title_short Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
title_sort expansion of tumor-infiltrating lymphocytes (til) from human pancreatic tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067894/
https://www.ncbi.nlm.nih.gov/pubmed/27777771
http://dx.doi.org/10.1186/s40425-016-0164-7
work_keys_str_mv AT hallmaclean expansionoftumorinfiltratinglymphocytestilfromhumanpancreatictumors
AT liuhao expansionoftumorinfiltratinglymphocytestilfromhumanpancreatictumors
AT malafamokenge expansionoftumorinfiltratinglymphocytestilfromhumanpancreatictumors
AT centenobarbara expansionoftumorinfiltratinglymphocytestilfromhumanpancreatictumors
AT hodulpamelaj expansionoftumorinfiltratinglymphocytestilfromhumanpancreatictumors
AT pimientojose expansionoftumorinfiltratinglymphocytestilfromhumanpancreatictumors
AT pilonthomasshari expansionoftumorinfiltratinglymphocytestilfromhumanpancreatictumors
AT sarnaikamoda expansionoftumorinfiltratinglymphocytestilfromhumanpancreatictumors